Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2070 in Homozygous Familial Hypercholesterolemia
NCT07591298Phase 2Recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- May 2026
- Primary completion
- Sep 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SYH2070 in familial hypercholesterolemia (FH) (2 arms), sponsored by CSPC Zhongnuo Pharmaceutical. Primary endpoint: Percentage change in serum Low-Density Lipoprotein Cholesterol level at 24 weeks. Started May 2026; status: recruiting.
02
Drugs
SYH2070
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT07591298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591298.